Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation (PODD) Free cash flow margin
Insulet Corporation's free cash flow margin over the twelve months to 30 June 2026 was 8.70%, down 4.2 percentage points from fiscal 2025 (12.9%). Over the past ten years it has ranged from −22.4% (fiscal 2018) to 14.3% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −7.24% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 12.9% | (1.38) |
| FY2024 | 14.3% | 12.15 |
| FY2023 | 2.15% | 5.08 |
| FY2022 | −2.93% | 14.43 |
| FY2021 | −17.4% | (8.24) |
| FY2020 | −9.12% | 0.70 |
| FY2019 | −9.82% | 12.62 |
| FY2018 | −22.4% | (14.70) |
| FY2017 | −7.74% | (6.05) |
| FY2016 | −1.69% | 7.09 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GMED Globus Medical, Inc. compare | 24.0% |
| HAE Haemonetics Corporation compare | 21.6% |
| PEN Penumbra, Inc. compare | 14.4% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 13.6% |
| BIO Bio-Rad Laboratories, Inc. compare | 13.6% |
| PODD Insulet Corporation | 8.70% |
| BRKR Bruker Corporation compare | 2.68% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| GKOS Glaukos Corporation compare | −1.99% |
| Medical Devices industry median | −7.24% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement